Future Science Group
MO8833A_supplementary_materials_v2_Figures.pdf (646.42 kB)

Supplementary Figures – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer

Download (646.42 kB)
posted on 2022-01-25, 09:05 authored by Figshare Future Science GroupFigshare Future Science Group, Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi

Figure S1

Kaplan–Meier curves before matching adjustment for a) overall survival b) progression-free survival

Figure S2

Forest plot of pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS 1–49% and ≥50%a


Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.